Renal Cell Carcinoma: Review of 26 Years of Experience at the Ochsner Clinic

Ochsner, M. Gage; Brannan, William; Pond, Harry S.; Goodier, Elbert H.

doi:10.1016/s0022-5347(17)60303-3

Cited by 52 publications

(14 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…After this report, many studies were per formed on this subject [10]. Besides reports that ESR has a prognostic value, there are others that refute this finding [7,8,[10][11][12][13][14], We found the ESR levels to be higher in RCCa patients that in the control group (78.182 ± 8.686 and 18.133 ± 2.189 mm/h, respectively (p < 0.001)). Best [15] found in 1987 that ESR levels were high in 43% of cases with renal tumors and Boxer et al [7] found the same result in 50% of their patients.…”

Section: Discussionmentioning

confidence: 56%

See 1 more Smart Citation

Erythrocyte Sedimentation Rates in Patients with Renal Cell Carcinoma

Dönmez¹,

Kale²,

Özyürek³

et al. 1992

Eur Urol

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 56%

“…Best [15] found in 1987 that ESR levels were high in 43% of cases with renal tumors and Boxer et al [7] found the same result in 50% of their patients. Ochsner et al [10] found 50% ESR rise in their series with 103 cases. In a study of 400 cases done at the Mayo Clinic, high levels of ESR were detected in 66 % of patients [16].…”

Section: Discussionmentioning

confidence: 84%

Erythrocyte Sedimentation Rates in Patients with Renal Cell Carcinoma

Dönmez¹,

Kale²,

Özyürek³

et al. 1992

Eur Urol

View full text Add to dashboard Cite

“…Several investigators also reported that the survival of patients with tumor thrombi without metastasis was similar to that of patients with stage I disease. 4,12,14,15 In our study, the 5-year causespecific survival in patients with tumor thrombi and no metastasis was (32%); the rate is similar to that of patients with stage II disease reported by Skinner et al 13 While the level of tumor thrombi did not affect survival in several studies, 6, 16 Sosa et al 17 reported that the patient's survival was correlated with tumor thrombi level; survival of patients with thrombi at a higher level was poorer than that of patients with thrombi at a lower level. Moreover, Montie et al 18 reported that the level of thrombus extending into the atrium was the distinguishing factor for survival assessment.…”

Section: Discussionmentioning

confidence: 99%

Surgical treatment of renal cell carcinoma with tumor thrombi in the inferior vena cava

et al. 1997

View full text Add to dashboard Cite

Background:We evaluated the results of surgical treatment for renal cell carcinoma with tumor thrombi in the inferior vena cava. Methods:Between March 1984 and July 1996, 25 patients were surgically treated for renal cell carcinoma with extension to the inferior vena cava. Inferior vena caval thrombosis was classified as supradiaphragmatic in 3 patients and infradiaphragmatic in 14 patients. Thrombi were also detected around the renal vein in 8 patients. Twenty-three patients underwent transperitoneal radical nephrectomy, and thrombectomy. One patient with bilateral renal cancer underwent right nephrectomy, left partial nephrectomy, and thrombectomy. The remaining patient underwent nephrectomy and an incomplete thrombectomy due to massive hemorrhage during surgery. In 10 patients with an inferior vena caval diameter of > 40 mm, a partial cardiopulmonary bypass was used during surgery. After removal of tumor thrombi, simple closure of the caval wall was performed in 14 patients, Gore-Tex TM (W.L. Gore 8, Associates, Elkton, MD, USA) patch grafting, in 10 patients, and inferior vena caval replacement with Gore-Tex, in 1 patient. Results:The 1-, 3-and 5-year cause-specific survival in all patients was (72%, 50%, and 23%), respectively. The mortality rate was (8%). There was no significant difference in cause-specific survival according to tumor thrombi level. However, the cause-specific survival of patients with metastasis to either regional lymph node or distant organs, or both (n = 10), was significantly lower compared to that of patients without metastasis (n = 15); the 3-year cause-specific survival was (17%) and (59%) in the metastasis group and the non-metastatic group, respectively (P= 0.042). ) Conclusien:These results indicate that removal of tumor thrombi in the inferior vena cava is a safe and useful treatment for renal cell carcinoma with no metastasis.Int J Clin Onco11997;2:213-218

show abstract

“…It became evident that the various cell types do have different effects on the prognosis, but these differ ences were relatively minor (table 1). With regard to the prognosis, the clear cell and chromophilic RCCs differ the most with the chromophilic cell RCCs promising the most favorable prognosis and the clear cell RCCs the least favorable [4,36,[42][43][44], There is no comparative data available for the chromophobic RCC, as it was not described in human beings until 1985 [45], With regard to the various growth patterns, clear dis tinctions in the prognosis can only be demonstrated occasionally. This is especially true for the cystic RCC (regularly clear cell), which exhibits an exceptionally good prognosis in our investigations (0% mortality rate).…”

Section: Discussionmentioning

confidence: 99%